Source access required
CVR360 has not loaded official Danish source data for this company yet. No AI or financial conclusion is generated without source-backed facts.
NT
Neumirna Therapeutics ApS
aktivCVR 41696451AnpartsselskabA.C. Meyers Vænge 15, 2450 København SVForskning og eksperimentel udvikling inden for naturvidenskab og teknik
- Latest accounts
- 2025
- Statement scope
- Standalone
- Verified
- 05 Nov 2026
- Sources
- 5
What changed?
Source-backed changes, not an assessment.
1 source
Key figures
Latest period: 2025
Revenue
Not available from the published filing—
Not available from the published filing
Operating profit
DKK -61.9m
Latest period
Source details
Source: dk-regnskabsdata-live-41696451-1793919502788
Document: dk-regnskabsdata-41696451-AZ8TePS6Y4y0EUXkvUUQ-1
XBRL: d:ProfitLossFromOrdinaryOperatingActivities
Period: 01 Jan 2025 - 31 Dec 2025
Technical details
Context: c1
Unit: u5
Net result
DKK -55.8m
Latest period
Source details
Source: dk-regnskabsdata-live-41696451-1793919502788
Document: dk-regnskabsdata-41696451-AZ8TePS6Y4y0EUXkvUUQ-1
XBRL: d:ProfitLoss
Period: 01 Jan 2025 - 31 Dec 2025
Technical details
Context: c1
Unit: u5
Equity
DKK 91.8m
Equity ratio: 91.5%
Source details
Source: dk-regnskabsdata-live-41696451-1793919502788
Document: dk-regnskabsdata-41696451-AZ8TePS6Y4y0EUXkvUUQ-1
XBRL: d:Equity
Period: 01 Jan 2025 - 31 Dec 2025
Technical details
Context: c7
Unit: u5
Development
Reported values. Missing periods appear as gaps.
RevenueNet result
Tabular view of development
| Year | Revenue | Net result |
|---|---|---|
| 2022 | — | DKK -5.3m |
| 2023 | — | DKK -8m |
| 2024 | — | DKK -7m |
| 2025 | — | DKK -55.8m |